Revolutionizing the Treatment of Autoimmune Diseases
About Us
Our Vision
Addressing significant unmet needs in the field of autoimmunity through the development of novel patented therapies for treatment of disease.
Latest News
Join us at the Antigen-Specific Immune Tolerance Drug Development Conference!
Dr. Sara Tezza will be presenting data on AnTolRx's antigen-specific nanoformulation platform. Join us in Boston March 26-28, 2019. http://as-immunetolerance.com
ANTOLRX ANNOUNCES PFIZER EXERCISES OPTION TO LICENSE IMMUNE TOLERANCE THERAPY FOR POTENTIAL TREATMENT OF TYPE 1 DIABETES
CAMBRIDGE, Mass., March 5,2019 – AnTolRx, Inc., a private biotechnology company and a leader in immune tolerance, today announced that Pfizer Inc. (NYSE: PFE) has exercised the option granted under a June 2016 agreement to license an immune...